an interactive automation experience – oncology … · an interactive automation experience ......
TRANSCRIPT
An Interactive Automation Experience –
Tami Hood
pOncology Cellular Assay Platform ( )
Tami HoodViraj Tyagi
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
OCAP Challenges
Assays
OCAP Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
3
Where?
Novartis Institute of Biomedical Research – Cambridge, MANovartis Institute of Biomedical Research – Cambridge, MA
4
Who? What?
Cellular Assays Team – OncologyCellular Assays Team – Oncology
Automate and streamline discovery of structure-activity relationships (SAR) using primary assaysAutomate and streamline discovery of structure-activity relationships (SAR) using primary assays
Project support for different targets
Automation consultation/support
Project support for different targets
Automation consultation/supportAutomation consultation/support
High-throughput data integration and analysis
Automation consultation/support
High-throughput data integration and analysis
5
Why?
Novartis: We want to discover, develop and successfully market innovative products to prevent and cure diseases to
Novartis: We want to discover, develop and successfully market innovative products to prevent and cure diseases tomarket innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want
to provide a shareholder return that reflects outstanding
market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life. We also want
to provide a shareholder return that reflects outstanding performance and to adequately reward those who invest
ideas and work in our company.performance and to adequately reward those who invest
ideas and work in our company.
Novartis Oncology: CURE CANCER!
6
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
Challenges
Assays
Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
7
Original challenges at Novartis Onc
All assays were in 96-well format (at best)All assays were in 96-well format (at best)
All dispensing was being done manually
Lack of trust in automated solutions
All dispensing was being done manually
Lack of trust in automated solutionsLack of trust in automated solutions
Fear that automation would take away jobs
Lack of trust in automated solutions
Fear that automation would take away jobs
Space constraints
Lack of equipment sharing
Space constraints
Lack of equipment sharing
“21st century science, 20th century technology” - Viraj“21st century science, 20th century technology” - Viraj
8
Oncology-specific needs
SAR for small-molecule projectsP i
SAR for small-molecule projectsP i• Primary
• Counter-screens• Secondary assays
• Primary• Counter-screens• Secondary assaysSecondary assays
Validation confirmation
Secondary assays
Validation confirmation
Exploratory screens
Biologics support
Exploratory screens
Biologics support
Automation support for assay development and automationAutomation support for assay development and automation
9
So...how can we support all this work and what kind of technology do we need?gy
| Presentation Title | Presenter Name | Date | Subject | Business Use Only10
Project Scope/Goals
Growing need for higher throughput and efficient assays more data for multiple target based projects
Growing need for higher throughput and efficient assays more data for multiple target based projectsmore data for multiple target-based projects
Desire for ONE system for seeding cells, dispensing reagents treating with compounds ambient/37C storage
more data for multiple target-based projects
Desire for ONE system for seeding cells, dispensing reagents treating with compounds ambient/37C storagereagents, treating with compounds, ambient/37C storage, labeling, and plate reading capabilities
Walk-up and easy-to-use system for numerous associates
reagents, treating with compounds, ambient/37C storage, labeling, and plate reading capabilities
Walk-up and easy-to-use system for numerous associatesWalk-up and easy-to-use system for numerous associates• Ownership
Offline use capabilities
Walk-up and easy-to-use system for numerous associates• Ownership
Offline use capabilitiesOffline use capabilitiesOffline use capabilities
11
Specific features desired
Flexible systemFlexible system
Safe, easy-to-use for users with varying automation backgroundsSafe, easy-to-use for users with varying automation backgrounds
User friendly interface
Compact footprint
User friendly interface
Compact footprintMarty
p p
Cost-effective (You listening Marty? Brian?)
p p
Cost-effective (You listening Marty? Brian?)
Most important: A vendor invested in our project, encompassing the care and concern we have for the ultimate customer: the patient!
Most important: A vendor invested in our project, encompassing the care and concern we have for the ultimate customer: the patient!pp
12
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
Challenges
Assays
Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
13
Unique approach
Classical Automation InDaHood approachLarge screening efforts (mostly single
point data)More automation of the routine daily
time-consuming tasksHit confirmation Multiple, simultaneous assays (low to
medium throughput in any data orientation)
Focused screens Shared resources (Open Access)One automation system = One assay Systems that can multi-task and run
overnight, unsupervisedStand-alone use and semi-modular
t tstrategyMultiple users
14
Vendors... Potential partners
Considered 4 vendorsConsidered 4 vendors
Desired:• Superior technology, design
Desired:• Superior technology, design• Commitment to excellence• Customer focus• Quick response
• Commitment to excellence• Customer focus• Quick response• Quick response• Outstanding service and applications partnering• Safety measures
• Quick response• Outstanding service and applications partnering• Safety measures• Reputation• Cost
P t l ti hi
• Reputation• Cost
P t l ti hi• Partner relationship• Partner relationship
15
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
Challenges
Assays
Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
17
Sample workflow
System setup “Cell seeding” protocol
Compound transfer
Place plates back
in hub “Add reagent”
protocolPlate read -
Envision(incubator)
protocolEnvision
19
OCAP Manual (non-OCAP)
Phase I vs. Phase II
Phase I Phase IIDDR robotic arm ATS 100 (Acoustic Transfer System)
Envision w/TRF laser Bravo Liquid HandlerEL406 Plate Washer/Dispenser VCode Barcode LabelerEL406 Plate Washer/Dispenser VCode Barcode Labeler
Liconic Steam Injected Incubator Plate Barcode ReaderAmbient Plate Hotel (Plate Hub) 3 docking tables
Liddi /D liddi t tiLidding/De-lidding station
22
Sample workflow w/Phase II
System setup “Cell seeding” protocol
Compound transfer
Place plates back
in hub “Add reagent”
protocolPlate read -
Envision(incubator)
protocolEnvision
23
OCAP Manual (non-OCAP)
OCAP Phase III and other additions
Phase III expansion still under considerationPhase III expansion still under consideration
Potential additions• EL406 for seeding multiple cell lines
Potential additions• EL406 for seeding multiple cell lines• Incubator• InCell (currently stand-alone)• Incubator• InCell (currently stand-alone)
Non-Biocel additions• Cell seeding/plate reading station with Benchbot
Non-Biocel additions• Cell seeding/plate reading station with Benchbot• InCell-Robot integration• InCell-Robot integration
25
Using the OCAP system, part I
Consultation visit with the scientistA t
Consultation visit with the scientistA t• Assay type
• Format• Throughput
• Assay type• Format• Throughput• Media (plate, tips, etc)• Future scope• Media (plate, tips, etc)• Future scope
Protocol development (VWorks, etc..)• Testing• Troubleshooting
Protocol development (VWorks, etc..)• Testing• Troubleshootingg
Inaugural protocol run with the scientist• Minor software/hardware training
g
Inaugural protocol run with the scientist• Minor software/hardware traininggg
26
Using the OCAP system, part II
2nd run with the scientistS i ti t t k h d t l
2nd run with the scientistS i ti t t k h d t l• Scientist takes hands-on control
Scientist responsible for running the assay• Available for further help teaching training and troubleshooting
• Scientist takes hands-on control
Scientist responsible for running the assay• Available for further help teaching training and troubleshooting• Available for further help, teaching, training, and troubleshooting• Continued support• Once scientist is comfortable running the assay, additional meetings to
f th th ll b ti di i ti th d t k l
• Available for further help, teaching, training, and troubleshooting• Continued support• Once scientist is comfortable running the assay, additional meetings to
f th th ll b ti di i ti th d t k lfurther the collaboration or discuss innovative methods take place
Our role: Facilitators
further the collaboration or discuss innovative methods take place
Our role: Facilitators
27
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
Challenges
Assays
Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
28
Challenges – Multiple users on system
CommunicationC l d b ki t Sh P i t
CommunicationC l d b ki t Sh P i t• Calendar booking system on SharePoint• Calendar booking system on SharePoint
29
Challenges – Multiple users on system
Multiple, simultaneous runsS i ti t 1 ll di
Multiple, simultaneous runsS i ti t 1 ll di• Scientist 1 – cell seeding
• Scientist 2 – reagent addition• Scientist 3 – compound spotting
• Scientist 1 – cell seeding• Scientist 2 – reagent addition• Scientist 3 – compound spotting
DEADLOCK!!DEADLOCK!!
Parameter changes in protocols difficult for users• FORMS!
Parameter changes in protocols difficult for users• FORMS!
Keeping environment and instruments contaminant-freeKeeping environment and instruments contaminant-free
30
Other challenges
Offline use of instruments –vital to successOffline use of instruments –vital to successvital to success• Low intimidation factor
EL406 access
vital to success• Low intimidation factor
EL406 accessEL406 access• Potential solution: Turntable
EL406 access• Potential solution: Turntable
31
Other challenges
Space limitationsZ t i t (DDR h)
Space limitationsZ t i t (DDR h)• Z-constraint (DDR reach)• Z-constraint (DDR reach)
32
Advantage of phase approach
Phase Approach – Instead of one massive project with multiple moving parts and instrumentation we decided on a phasedPhase Approach – Instead of one massive project with multiple moving parts and instrumentation we decided on a phasedmoving parts and instrumentation, we decided on a phased project (Phase I, II, III)
• Room for scope changes
moving parts and instrumentation, we decided on a phased project (Phase I, II, III)
• Room for scope changes
• Changes in instrumentation needs (new instruments needed or current ones unnecessary)
• Change in ideas/process based on initial usage of system can be
• Changes in instrumentation needs (new instruments needed or current ones unnecessary)
• Change in ideas/process based on initial usage of system can be• Change in ideas/process based on initial usage of system can be reflected in future phases
• Change in throughput needs
• Change in ideas/process based on initial usage of system can be reflected in future phases
• Change in throughput needs
• Change in design• Change in design
33
OCAP Time savings
Assay 1 (Proliferation Assay) – 384 well platesAssay 1 (Proliferation Assay) – 384 well plates
Manual (min) Automation (min)
Cell Seeding (20 plates) 90 20 (+10 min hands-on time)
Drugging (20 plates) 180+ 80 (+10 min hands-on time)
Reagent addition and read(20 plates)
100 60 (+5 min hands-on time)
Real life time savings example:• Veronica ran an assay that took 3 hours a day X 4 days a week = 12 hours
Real life time savings example:• Veronica ran an assay that took 3 hours a day X 4 days a week = 12 hours• Veronica ran an assay that took 3 hours a day X 4 days a week = 12 hours• With OCAP, her hands-on time is ~2.5 hours• Veronica ran an assay that took 3 hours a day X 4 days a week = 12 hours• With OCAP, her hands-on time is ~2.5 hours
Si ifi t ti iSignificant time savings
Support Reach
Currently, we support 16 labheads and ~25 associates for: • Small molecule drug discovery projects
Currently, we support 16 labheads and ~25 associates for: • Small molecule drug discovery projectsSmall molecule drug discovery projects• RNAi Screens• Combination screens
Small molecule drug discovery projects• RNAi Screens• Combination screens Projected to • Biologics projects
OCAP system1
• Biologics projects
OCAP system1
have ~25regular OCAP users by June • 1 superuser
• 2 regular users/trainers from our lab• 9 regular users from other labs across oncology
• 1 superuser• 2 regular users/trainers from our lab• 9 regular users from other labs across oncology
use s by Ju e2012
• In addition, many occasional users • In addition, many occasional users
35
Assay Types/Readouts
Routine Assays Run within Oncology Format Comment
Reporter Gene Assays 384Assays
Cellular Surefire 384
Translocation HCI 384
N clear Co nt HCI 384 I D l tNuclear Count HCI 384 In Development
Proliferation 384
Proliferation combinations and
triples384
triplesAGP/HSA Shift
assays 384
Caspase Activation 384
Quantification ofQuantification of metabolites 384
Medulloblastoma -neurosphere assay 384 In Development
Transient Transfection Dual 96
Luciferase
MSD Assays - prep 96 In Automation Optimization
Roadmap
Who are we? What do we do?
Original Challenges/Oncology needs
Who are we? What do we do?
Original Challenges/Oncology needsOriginal Challenges/Oncology needs
Project scope/features
Approach
Original Challenges/Oncology needs
Project scope/features
Approachpp
OCAP system details
Using the OCAP system
pp
OCAP system details
Using the OCAP system
Challenges
Assays
Challenges
Assays
Potential Improvements
Outlook
Potential Improvements
Outlook
SuggestionsSuggestions
37
Potential improvements
A single channel or 8 channel option on the BravoA single channel or 8 channel option on the Bravo
Continual optimization to decrease deadlocks
Turntables to allow access to instruments
Continual optimization to decrease deadlocks
Turntables to allow access to instruments
Greater z-reach for DDRs
Better docking tables
Greater z-reach for DDRs
Better docking tablesBetter docking tablesBetter docking tables
38
OCAP outlook
Benchtop integrated workstationsBenchtop integrated workstations• Relieve OCAP as use increases• Single task focus
- Cell seeding only
• Relieve OCAP as use increases• Single task focus
- Cell seeding only- Plate reading only
Phase III will be determined by the logistics of use over the next 6 months and where we see need to increase
- Plate reading only
Phase III will be determined by the logistics of use over the next 6 months and where we see need to increasethe next 6 months and where we see need to increase throughput, ease, bottlenecks the next 6 months and where we see need to increase throughput, ease, bottlenecks
39
Our Lab’s future vision
Fully functional, walk-away Biocel systemFully functional, walk-away Biocel system
Cell seeding and reading stations throughout lab space
Specialized readers (ie HCI Biacore MSD) become
Cell seeding and reading stations throughout lab space
Specialized readers (ie HCI Biacore MSD) becomeSpecialized readers (ie HCI, Biacore, MSD) become modular and/or stand alone with stackers/mini-arms while off system
Specialized readers (ie HCI, Biacore, MSD) become modular and/or stand alone with stackers/mini-arms while off system
1-2 power users with broad programming capabilities
Growing users that can train one another
1-2 power users with broad programming capabilities
Growing users that can train one anotherGrowing users that can train one another
Full Schedule both day and night
Growing users that can train one another
Full Schedule both day and night
More time to interact with data sets More time to interact with data sets 40
Suggestions, based on our experiences...Part I
New projects and users should give adequate notice then set appropriate expectations as to when their solutions can be put in place and full use of New projects and users should give adequate notice then set appropriate expectations as to when their solutions can be put in place and full use of p p presources can commence
Have a good interactive computer-based scheduling system
p p presources can commence
Have a good interactive computer-based scheduling system
Strongly encourage all associates to be trained on Instruments and Equipment as an opportunity for future successes and streamlining
Ensure that you understand the scope and timelines of projects
Strongly encourage all associates to be trained on Instruments and Equipment as an opportunity for future successes and streamlining
Ensure that you understand the scope and timelines of projects
Standardize as much as possible – be creative – think out of the box
Be courteous, supportive (even on your worst day) – no fear or question h ld dd d
Standardize as much as possible – be creative – think out of the box
Be courteous, supportive (even on your worst day) – no fear or question h ld dd dshould go unaddressed
Decide together on Data solutions
should go unaddressed
Decide together on Data solutions
41
Suggestions, based on our experiences...Part II
Have a list of all contacts involved in the Project in order to provide sufficient communicationHave a list of all contacts involved in the Project in order to provide sufficient communicationcommunication
Stay in the project loop as appropriate – meet as frequently as necessary to get them onboard
communication
Stay in the project loop as appropriate – meet as frequently as necessary to get them onboard
Acquire a patient, flexible staff with excellent communication skills
Partner with each and every lab utilizing the facility
Acquire a patient, flexible staff with excellent communication skills
Partner with each and every lab utilizing the facility
Superuser - preferably an engineer, Assay Development specialist in DA specific areaSuperuser - preferably an engineer, Assay Development specialist in DA specific area
42
Agilent Technologies• Jeff HsuAgilent Technologies• Jeff Hsu
Waste hole phenomenon• Jeff Hsu• Marty Thomae• Pete Werner
• Jeff Hsu• Marty Thomae• Pete Werner• Brian O’Sullivan• Robert Vandenburg• Steve Ciaccio
• Brian O’Sullivan• Robert Vandenburg• Steve Ciaccio• OCAP project team
Novartis
• OCAP project team
Novartis• Chris Igo• Ted Manley• Brian Duffy
• Chris Igo• Ted Manley• Brian DuffyBrian Duffy• Cellular Assays Team
Brian Duffy• Cellular Assays Team
43